<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03929900</url>
  </required_header>
  <id_info>
    <org_study_id>KNOW-CKD2</org_study_id>
    <nct_id>NCT03929900</nct_id>
  </id_info>
  <brief_title>KNOW-CKD Cohort, Phase II Study</brief_title>
  <official_title>KoreaN Cohort Study for Outcome in Patients With Chronic Kidney Disease: A Longitudinal Cohort Study of the Chronic Kidney Disease (KNOW-CKD), Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goals of KNOW-CKD (KoreaN cohort study for Outcome in patients With Chronic Kidney&#xD;
      Disease) study are 1) to establish a CKD cohort representing Korean CKD population for up to&#xD;
      10-year follow-up, and 2) to investigate the renal progression, mortality, complications,&#xD;
      risk factors, role of biochemical parameters and the genetic influence. KNOW-CKD Phase I has&#xD;
      enrolled 2,238 patients and these patients were divided into four major subgroups depending&#xD;
      on the specific causes of CKD : glomerulonephritis, diabetic nephropathy, hypertensive&#xD;
      nephropathy, and polycystic kidney disease. In progress, renal progression, complications,&#xD;
      and cardiovascular disease of these patients are followed up now.&#xD;
&#xD;
      Since there was a lack of information related to patients' lifestyle, it is necessary to&#xD;
      conduct various studies that can be applied to actual clinical status through evaluation of&#xD;
      nutrition, cognitive functions, and lifestyles of patients with CKD in South Korea. In&#xD;
      addition, researches for high risk patients including diabetic nephropathy, advanced CKD and&#xD;
      elderly patients are needed. Thus, KNOW-CKD phase II will enroll the CKD subjects at a more&#xD;
      advanced-stage, and older patients than KNOW-CKD phase I subjects.&#xD;
&#xD;
      KNOW-CKD phase II Investigator Group comprises nephrologists, epidemiologists and&#xD;
      statisticians from multi-centers in South Korea. KNOW-CKD phase II will enroll 1,500&#xD;
      individuals with estimated glomerular filtration rate between 20 and 60mL/min/1.73m2&#xD;
      (CKD-EPI[Cr] equation) between 2019 and 2021 and follow them until 2016 (for 5~7 years).&#xD;
      Unlike phase I, patients diagnosed with glomerulonephritis and ADPKD will be excluded in&#xD;
      Phase II.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At enrollment and at pre-specified intervals, laboratory tests will be conducted on the&#xD;
      kidney function, biochemical profiles, and anemia. Nutritional evaluation through skin fold,&#xD;
      hand grip test, bioelectrical impedence analysis, and 7-point subjective global assessment&#xD;
      (SGA), food frequency questionnaire (FFQ) will be conducted in a subgroup of patients.&#xD;
      Information on the medical history, health questionnaires, QOL, K-MoCA will also be&#xD;
      collected. Web-based case-report forms (CRF) will be used for the systematic management of&#xD;
      the patient data.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 15, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall mortality</measure>
    <time_frame>5 years</time_frame>
    <description>all-cause death, cardiovascular death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular event</measure>
    <time_frame>5 years</time_frame>
    <description>major cardiovascular event (MACE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal replacement therapy</measure>
    <time_frame>5 years</time_frame>
    <description>end-stage renal disease : dialysis or kidney transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Doubling of serum creatinine or eGFR halving</measure>
    <time_frame>5 years</time_frame>
    <description>Doubling of serum creatinine or eGFR halving</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Chronic Kidney Diseases</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      DNA, serum, plasma, random urine will be collected at pre-specified interval&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        non-dialysis-dependent, advanced CKD stage between 45 -79 years&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 45-79 years&#xD;
&#xD;
          -  Estimated glomerular filtration rate 20-60mL/min/1.73m2 based on CKD-EPI(Cr) equation&#xD;
&#xD;
          -  Non-dialysis dependent (NDD)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Autosomal dominant polycystic kidney disease&#xD;
&#xD;
          -  Unable or unwilling to give consent&#xD;
&#xD;
          -  Previously received chronic dialysis&#xD;
&#xD;
          -  Previous any organ transplant&#xD;
&#xD;
          -  Patients who diagnosed heart failure with NYHA class 3 or 4&#xD;
&#xD;
          -  Known liver cirrhosis (Child-pugh class 2 or 3)&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Single kidney due to trauma or donation&#xD;
&#xD;
          -  Patients who received immunosuppressive agent within the past 1 year&#xD;
&#xD;
          -  Patients who diagnosed with glomerulonephritis through kidney biopsy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kook-Hwan Oh, MD</last_name>
    <phone>82 2 2072 0776</phone>
    <email>khoh@snu.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Jongno-gu</state>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kook-Hwan Oh, MD</last_name>
      <phone>82 2 2072 0776</phone>
      <email>khoh@snu.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>April 25, 2019</study_first_submitted>
  <study_first_submitted_qc>April 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2019</study_first_posted>
  <last_update_submitted>June 3, 2019</last_update_submitted>
  <last_update_submitted_qc>June 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Kook-Hwan Oh</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Renal progression</keyword>
  <keyword>Mortality</keyword>
  <keyword>Complications</keyword>
  <keyword>Risk factors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

